Related Experiment Video

Updated: Mar 16, 2026

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
12:24

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

6.3K

The challenges of multi-drug-resistance in hepatology

Javier Fernández1, Frédéric Bert2, Marie-Hélène Nicolas-Chanoine3

  • 1Liver Unit, Hospital Clínic Barcelona, University of Barcelona, Spain; Institut d'Investigacions Biomèdiques August-Pi-Sunyer (IDIBAPS), Spain; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHED), Spain.

Journal of Hepatology
|August 22, 2016
PubMed

Insights

Antimicrobial resistance is a global health crisis, particularly impacting patients with decompensated cirrhosis due to increased susceptibility and limited treatment options. New strategies are crucial to combat resistant infections in this vulnerable population.

Area of Science:

  • Public Health
  • Infectious Diseases
  • Hepatology

Background:

  • Antimicrobial resistance (AMR) is a significant global health threat, driven by antibiotic overuse and inadequate infection control.
  • Resistant bacterial infections, including multi-drug and pan-drug resistant strains, are increasing worldwide.
  • Decompensated cirrhosis patients face heightened susceptibility to resistant infections due to factors like frequent hospitalizations and antibiotic exposure.

Purpose of the Study:

  • To highlight the critical challenge of antimicrobial resistance in decompensated cirrhosis.
  • To discuss the increased morbidity and mortality associated with resistant infections in cirrhotic patients.
  • To propose strategies for combating AMR in this population.

Main Methods:

  • Review of current literature on antimicrobial resistance in cirrhosis.
  • Analysis of risk factors and clinical outcomes in cirrhotic patients with resistant infections.
  • Discussion of preventive measures and therapeutic strategies.

Main Results:

  • Cirrhotic patients exhibit a high risk for infections caused by resistant bacteria.
  • Inappropriate antibiotic regimens in cirrhosis lead to severe complications like acute kidney injury, liver failure, and septic shock.
  • Limited therapeutic options are available for treating resistant bacterial infections.

Conclusions:

  • Hepatologists must adopt new empirical antibiotic strategies to manage resistant infections in cirrhosis.
  • Implementing global, regional, and local preventive measures is essential, including restricted antibiotic prophylaxis, non-antibiotic prophylaxis research, stewardship programs, and rapid diagnostics for de-escalation.
  • Enhanced infection control practices and surveillance programs are vital for combating AMR in cirrhosis.
Keywords:
Antibiotic prescriptionsAntimicrobial resistanceDe-escalationEpidemiological surveillanceExtensively drug-resistantMortalityMulti-drug-resistanceNew antibioticsPan-drug-resistancePreventionPrognosisStewardship programs

More Related Videos

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

11.2K
Quadruple-Checkerboard: A Modification of the Three-Dimensional Checkerboard for Studying Drug Combinations11:15

Quadruple-Checkerboard: A Modification of the Three-Dimensional Checkerboard for Studying Drug Combinations

Published on: July 24, 2021

5.6K

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
312
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug01:14

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
277
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
248
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
324
Hepatic Drug Excretion: Influencing Factors01:16

Hepatic Drug Excretion: Influencing Factors

The biliary system of the liver, crucial for bile secretion and drug excretion, comprises intrahepatic bile ducts that merge to form the common hepatic duct. This duct, carrying hepatic bile, combines with the cystic duct, draining the gallbladder and forming the common bile duct, which empties into the duodenum. Bile, produced by hepatic cells lining the bile canaliculi, is composed primarily of water, bile salts, pigments, electrolytes, and lesser amounts of cholesterol and fatty acids. Bile...
705
Drug toxicity: Drug–Drug Interaction01:30

Drug toxicity: Drug–Drug Interaction

Drug–drug interactions can precipitate toxicity through multiple mechanisms. Absorption interactions alter how drugs enter the body, exemplified when ranitidine increases the absorption of basic drugs, while cholestyramine decreases the levels of propranolol. Protein binding interactions occur when drugs share the same binding sites on plasma proteins. Drugs like aspirin and warfarin, when bound in excess, can lead to increased free drug concentrations, enhancing the potential for...
238